**S7 Table. Proportion of participants presenting splenomegaly at D60 of follow-up**

|  |  |  |  |
| --- | --- | --- | --- |
| Treatment  | % of participants with splenomegaly  | Difference in % of participants with splenomegaly versus comparator - % (95% CI) | P-value (χ2) |
| MA (Comparator) | 26.4 (24/91) |   |   |
| LAMB | 33.0 (31/94) | 6.6 (-6.53 to 19.72) | 0.326a |
| LAMB +MA | 24.5 (24/98) | -1.9 (-14.33 to 10.53) | 0.766b |
| Total  | 27.9 (79/283) |   |   |

MA = meglumine antimoniate; LAMB = liposomal amphotericin B; LAMB+MA = treatment combination liposomal amphotericin B and meglumine antimoniate; a P-value calculated for LAMB versus MA; b P-value calculated for LAMB+MA versus MA.